Adam Weiner, Urologic Surgeon at Cedars-Sinai, shared a post on X about a paper by Amar Kishan et.al published in JCO ASCO:
“LUNAR phase II trial RCT of patients with Oligorecurent Hormone-Sensitive Prostate Cancer
Patients (n=92) randomized 1:1 to SBRT alone or ¹⁷⁷Lu-PNT2002 followed by SBRT
PFS doubled: 17.6 mo vs 7.4 months (HR 0.37, P<.0001)
>50% PSA drops in 52% vs 31%
Fewer new lesions on PSMA PET
No added toxicity with Lu-PNT2002 + SBRT
First randomized trial bringing PSMA-RLT earlier in orHSPC.”
Title: 177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study
Authors: Amar U. Kishan, Luca F. Valle, Holly Wilhalme, Carol Felix, Rejah Nabong, Jesus E. Juarez-Casillas, Kevin Flores, T. Martin Ma, Vinicius Ludwig, Mariko Nakayama, Zachary Ells, Magnus Dahlbom, Michael Lauria, Catherine Meyer, Minsong Cao, Joanne B. Weidhaas, Donatello Telesca, Kristen McGreevy, Nicholas G. Nickols, Danielle Karasik, Sophia Parmisano, T. Vincent Basehart, Wayne Brisbane, Leonard Marks, Matthew B. Rettig, Robert E. Reiter, Paul C. Boutros, Martin Allen-Auerbach, Johannes Czernin, Michael L. Steinberg, Jeremie Calais
You can read the full article in JCO ASCO.
More posts featuring Adam Weiner.